Drug Trial Radar · NCT01790503
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Last checked: Nov 20, 2026Latest source record: Jun 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Jul 18, 2013
Primary completion
Nov 3, 2017
Study completion Mar 4, 2020
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Plexxikon
- First posted
- Feb 13, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
Conditions
- Patients With Newly Diagnosed Glioblastoma
Interventions
PLX3397Drug
Radiation TherapyRadiation
TemozolomideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of the Median Progression-free Survival (mPFS) in the Combined 800 mg, 5 Days/Week Dose GroupTime frame: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
- Summary of the Median Progression-free Survival (mPFS) in the Study Group Compared With Historical Control From Medical LiteratureTime frame: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Northwestern Memorial Hospital
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Columbia University Medical Center
New York, New York
James Cancer Hospital/Ohio State University
Columbia, Ohio
Huntsman Cancer Institute University of Utah
Salt Lake City, Utah
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.